Patent US4381302A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4381302A Expired / Lapsed US ⏱️ 0.0 years remaining

(6aα,10aα,11aα)-2-(2-Pyridinyl)-1,3,4,6,6a,7,8,9,10,10a,11,11a-dodecahydro-2H-pyrazino]1,2-b]isoquinoline and derivatives

Assignee: Merck and Co Inc
•
Filing: 1981-05-26
•
Granted: 1983-04-26
•
Expires: 2001-05-26
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract (6a alpha ,10a alpha ,11a alpha )-2-(2-pyridinyl)-1,3,4,6,6a,7,8,9,10,10a,11,11a-dodecahydro-2H-pyrazi no[1,2-b]isoquinoline and derivatives or acid addition salts thereof are selective alpha 2-adrenergic receptor antagonists and thereby useful as antidepressant agents and for treating sedation caused by antihypertensive therapy.

Inventors

  • 👤 Joel R. Huff
  • 👤 Stella W. King
  • 👤 Walfred S. Saari

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-28 10:03
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/02; C07D471/04; C07D217/00; C07D217/22; C07D217/26

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 60 words
A method of selectively antagonizing α 2 -adrenergic receptors in a patient in need of such treatment which comprises the administration of an effective amount of a compound of structural formula: ##STR4## or a pharmaceutically acceptable salt thereof wherein R is (1) hydrogen, (2) halo, (3) C 1-4 alkyl, (4) cyano, (5) C 1-4 alkoxy, (6) trifluoromethyl, or (7) nitro.
Claim 2
Independent Claim 60 words
A method of selectively antagonizing α 2 -adrenergic receptors in a patient in need of such treatment which comprises the administration of an effective amount of a compound of structural formula: ##STR4## or a pharmaceutically acceptable salt thereof wherein R is (1) hydrogen, (2) halo, (3) C 1-4 alkyl, (4) cyano, (5) C 1-4 alkoxy, (6) trifluoromethyl, or (7) nitro.
Claim 3
Dependent Claim 16 words
The method of claim 1 wherein R is hydrogen, fluoro, methyl, cyano, methoxy, trifluoromethyl or nitro.
Claim 4
Dependent Claim 11 words
The method of claim 2 wherein R is hydrogen or fluoro.
Claim 5
Dependent Claim 34 words
A compound of structural formula: ##STR5## or a pharmaceutically acceptable salt thereof, wherein R is (1) hydrogen, (2) halo, (3) C 1-4 alkyl, (4) cyano, (5) C 1-4 alkoxy, (6) trifluoromethyl, or (7) nitro.
Claim 6
Dependent Claim 34 words
A compound of structural formula: ##STR5## or a pharmaceutically acceptable salt thereof, wherein R is (1) hydrogen, (2) halo, (3) C 1-4 alkyl, (4) cyano, (5) C 1-4 alkoxy, (6) trifluoromethyl, or (7) nitro.
Claim 7
Dependent Claim 16 words
The compound of claim 4, wherein R is hydrogen, fluoro, methyl, cyano, methoxy, trifluoromethyl or nitro.
Claim 8
Dependent Claim 11 words
The compound of claim 5, wherein R is hydrogen or fluoro.
Claim 9
Dependent Claim 60 words
A selective α 2 -adrenergic receptor antagonist pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and an effective α 2 -adrenergic receptor antagonist amount of a compound of structural formula: ##STR6## or a pharmaceutically acceptable salt thereof wherein R is (1) hydrogen, (2) halo, (3) C 1-4 alkyl, (4) cyano, (5) C 1-4 alkoxy, (6) trifluoromethyl, or (7) nitro.
Claim 10
Dependent Claim 60 words
A selective α 2 -adrenergic receptor antagonist pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and an effective α 2 -adrenergic receptor antagonist amount of a compound of structural formula: ##STR6## or a pharmaceutically acceptable salt thereof wherein R is (1) hydrogen, (2) halo, (3) C 1-4 alkyl, (4) cyano, (5) C 1-4 alkoxy, (6) trifluoromethyl, or (7) nitro.
Claim 11
Dependent Claim 17 words
The pharmaceutical composition of claim 7 wherein R is hydrogen, fluoro, methyl, cyano, methoxy, trifluoromethyl or nitro.
Claim 12
Dependent Claim 12 words
The pharmaceutical composition of claim 8 wherein R is hydrogen or fluoro.

References Cited (Backward Citations)

US2958694A Cited
US3773951A Cited
US4081542A Cited
US4082844A Cited
US4078063A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1986-04-25 1986-10-25 1987-04-26 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1990-04-25 1990-10-25 1991-04-26 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1994-04-25 1994-10-25 1995-04-26 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag